SIRT1 represents a mechanistically validated target with notable progress in early-stage drug development for MASLD. With further in-depth analysis of its regulatory network and continued optimization ...
A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback